The 'typical' immunophenotype of acute promyelocytic leukemia (APL-M3): Does it prove true for the M3-variant?

Communications in Clinical Cytometry

Volumn 42, Issue 2, 2000, Pages 106-109

  Exner, Markus ^a   Thalhammer, Renate ^a   Kapiotis, Stylianos ^a   Mitterbauer, Gerlinde ^a   Knöbl, Paul ^a   Haas, Oskar A ^b   Jäger, Ulrich ^a   Schwarzinger, Ilse ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Acute promyelocytic leukemia; Immunophenotype; M3 variant

Indexed keywords

CD2 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; HLA DR ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW CELL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; PRIORITY JOURNAL;

EID: 0034656146     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(20000415)42:2<106::AID-CYTO3>3.0.CO;2-S     Document Type: Article

References (25)

1. Arber DA, Jenkins KA, Slovak ML. CD79α expression in acute myeloid leukemia. Am J Pathol 1996;149:1105-1110.
2. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. A variant form of hypergranular promyclocytic leukemia (M3). Ann Intern Med 1980;44:169-170.
3. Biondi A, Luciano A, Bassan R, Mininni D, Specchia G, Lanzi E, Castagna S, Cantu-Rajnoldi A, Liso V, Masera G, Barbui T, Rambaldi A. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia 1995;9:1461-1466.
4. Bradbury DA, Aldington S, Zhu Y-M, Russel NH. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol 1996;94:671-675.
5. Castoldi GL, Liso V, Specchia G, Tomasi P. Acute promyelocytic leukemia: morphological aspects. Leukemia 1994;8:S27-S32.
6. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukaemia. Blood 1992;80:582-586.
7. De Rossi G, Avvisati G, Coluzzi S, Fenu S, Lo Coco F, Lopez M, Nanni M, Pasqualetti D, Mandelli F. Immunological definition of acute promyelocytic leukaemia (FAB M3): a study of 39 cases. Eur J Haematol 1990;45:168-171.
8. Di Noto R, Pardo CL, Schlavone EM, Manzo C, Vacca C, Ferrara F, Del Vecchio L. Stem cell factor receptor (c-kit, CD117) is expressed on blast cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukaemia. Br J Haematol 1996;92:562-564.
9. Erber WN, Ashbar H, Rule SA, Scott CS. Unique phenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies. Br J Haematol 1994;88:101-104.
10. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 1997;90:4046-4053.
11. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr. All-trans relinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994;120: 278-286.
12. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Biondi A, Cocito MG, Del Vecchio L, Tabilio A, Avvisati G, Basso G, Lo Loco F. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 1998;102:1035-1041.
13. Haas OA, Schwarzmeier JD, Nacheva E, Fischer P, Paietta E. Investigations on karyotype evolution in patients with chronic myeloid leukemia (CML). Blut 1984;48:33-43.
14. Laczika K, Mitterbauer G, Korninger L, Knöbl P, Schwarzinger I, Kapiotis S, Haas OA, Kyrle PA, Pont J, Oehler L, Purtscher B, Thalhammer F, Lechner K, Jaeger U. Rapid achievement of PML-RARα polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia 1994;8:1-5.
15. Lo Coco F, Avvisati G, Diverio D, Biondi A, Pandolfi PP, Alcalay M, De Rossi G, Petti MC, Cantu-Rajnoldi A, Pasqualetti D, Nanni M, Fenu S, Frontani M, Mandelli F. Rearrangements of RAR-α gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype. Br J Haematol 1991;78:494-499.
16. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute pramyelocytic leukemia. Blood 1999;94:12-22.
17. ISCN (1995). An international system for human cytogenetic nomenclature, Midelman F (editor). Basel: Karger; 1995.
18. Murray CK, Estey E, Paietta E, Howard RS, Edensfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999;17:293-297.
19. Paietta E, Anderson J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik PH. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia 1994;8:1108-1112.
20. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchinson JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58:1203-1212.
21. Schwarzinger I, Valent P, Köller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K, Bettelheim P. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990;8:423-430.
22. Scott AA, Head DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR, Chen IM, Whittaker MH, Griffith BB, Licht JD, Waxman S, Whalen MM, Bankhurst AD, Richter LC, Grogan TM, Willman CL. HLA-DR-, CD33+, CD56+, CD16-myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 994;84:244-255.
23. Solary E, Casasnovas RO, Campos L, Bene MC, Faure G, Maingon P, Falkenrodt A, Lenormand B, Genetet N. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Leukemia 1992;6:393-399.
24. Stasi R, Bruno A, Venditti A, Del Poeta G, Aronica G, Cox MC, Maffei L, Catalano G, Zangrilli D, Amadori S. A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. Leukemia Res 1997;21:575-580.
25. Warrell RP, De Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. New Engl J Med 1993;329:177-189.